



PROPRIETARY
TECHNOLOGY TO
PERSONALIZE THE
DEVELOPMENT AND
USE OF CANCER
MEDICINES



ANGEL GARCIA MARTIN
PhD, MBA

Founder and CEO


THE PROBLEM WITH ONCOLOGY DRUGS

FAILURE REMAINS HIGH: < than 10%
chance of approval in clinical trials




COSTS SKYROCKETING:

- \$1.2 B development cost per drug
- average \$ 11,000/ month for new cancer drugs



**PATIENT RESPONSE TO TREATMENT
REMAINS LOW**




GAP IN TRANSLATION FROM THE LAB TO THE CLINIC



CONVENTIONAL (2D) TUMOR CELL MODELS:

- Available since early 1900s
- Easy, accessible
- Obsolete models, lack predictability

BIOLOGY IS NOT FLAT! ADD DIMENSION TO FILL THIS GAP



3D-cell tumor models recreate the natural architecture of the tumor

3D-cell tumor models predict drug activity

CURRENT TECHNOLOGY NOT USER FRIENDLY



AFTER YEARS OF LABORATORY WORK, STEMTEK HAS DEVELOPED
AN INNOVATIVE SOLUTION TO FILL THIS GAP.


CELL2SPHERE™

by Stemtek

- ✓ A unique and innovative PATENTED 3D spheroid technology.
- ✓ First ALL-IN-ONE, STORABLE product, ready to use at any time.
- ✓ REDUCES 88% TIME to results, 70% CHEAPER.



BUSINESS STRATEGY



THINK 3D!

www.stemtektherapeutics.com



agmartin@stemtektherapeutics.com



[/stemtek-therapeutics](https://www.linkedin.com/company/stemtek-therapeutics)



[@StemTekTher](https://twitter.com/StemTekTher)



[/stemtek-therapeutics](https://www.facebook.com/stemtek-therapeutics)

